AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Mefexamide hydrochloride is believed to exert its effects by acting as a muscle relaxant, potentially reducing muscle spasms and stiffness.
Central Nervous System (CNS) Effects: Like other muscle relaxants, mefexamide hydrochloride may have central nervous system effects. These can include drowsiness, dizziness, and sedation. Patients taking mefexamide hydrochloride should be cautious when operating machinery or driving until they understand how the medication affects them.
Adverse Reactions: While specific adverse reactions associated with mefexamide hydrochloride may vary, common side effects of muscle relaxants in general can include nausea, vomiting, headache, blurred vision, dry mouth, and constipation.
Drug Interactions: Mefexamide hydrochloride may interact with other medications, including other muscle relaxants, opioids, benzodiazepines, and alcohol. Patients should inform their healthcare providers about all medications they are taking to avoid potential interactions.
Contraindications: Mefexamide hydrochloride may be contraindicated in individuals with certain medical conditions, such as myasthenia gravis, liver disease, or kidney disease. It is important for healthcare providers to review a patient's medical history thoroughly before prescribing mefexamide hydrochloride.
Pregnancy and Lactation: There may be limited data available on the safety of mefexamide hydrochloride use during pregnancy and breastfeeding. Pregnant or breastfeeding individuals should consult their healthcare provider before taking this medication.
Discontinuation: As with any medication, mefexamide hydrochloride should be discontinued gradually under the guidance of a healthcare provider to avoid potential withdrawal symptoms or rebound effects.
Monitoring: Patients taking mefexamide hydrochloride may require monitoring for effectiveness and potential side effects, especially during the initial stages of treatment or when adjusting the dosage.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 4.2 | 0.3 | 13 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.6 | 0.08 |
| Allergies | 6 | 2.9 | 1.07 |
| Allergy to milk products | 2.1 | 1.6 | 0.31 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 5.8 | 5.1 | 0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 1.4 | 1.07 |
| Ankylosing spondylitis | 4.1 | 1.2 | 2.42 |
| Anorexia Nervosa | 1.6 | 2.7 | -0.69 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 5.2 | 2.8 | 0.86 |
| Atherosclerosis | 2.5 | 1.4 | 0.79 |
| Atrial fibrillation | 3.3 | 1.6 | 1.06 |
| Autism | 6.7 | 7.6 | -0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 2.3 | -1.56 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 2.2 | 3.5 | -0.59 |
| Cerebral Palsy | 1.6 | 1.3 | 0.23 |
| Chronic Fatigue Syndrome | 3.6 | 3.8 | -0.06 |
| Chronic Kidney Disease | 3.6 | 1.4 | 1.57 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.7 | 0.29 |
| Chronic Urticaria (Hives) | 2 | 0.8 | 1.5 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 7.1 | 2.2 | 2.23 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 2.1 | 1.9 | 0.11 |
| COVID-19 | 7.9 | 7.4 | 0.07 |
| Crohn's Disease | 6.7 | 4.9 | 0.37 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.2 | 1.6 | -0.33 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.1 | 1.4 | 1.21 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 9.1 | 7.7 | 0.18 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.8 | -0.06 |
| Endometriosis | 3.2 | 2.3 | 0.39 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.7 | 2 | 0.85 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 2.8 | 1 | 1.8 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.2 | 0.53 |
| gallstone disease (gsd) | 3.6 | 1.3 | 1.77 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.2 | 0.08 |
| Generalized anxiety disorder | 2.4 | 2.2 | 0.09 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.7 | 2 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 1.4 | -1.33 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.4 | 1.1 | 2.09 |
| Heart Failure | 3.7 | 1.5 | 1.47 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.7 | 0.6 | 1.83 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.5 | 1.2 |
| hyperglycemia | 2.7 | 1.8 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.4 | 4.2 | 0.05 |
| Hypothyroidism | 0.2 | 0.4 | -1 |
| Hypoxia | 3.5 | 0.3 | 10.67 |
| IgA nephropathy (IgAN) | 1.6 | 2.8 | -0.75 |
| Inflammatory Bowel Disease | 7.2 | 7.1 | 0.01 |
| Insomnia | 1.9 | 2.8 | -0.47 |
| Intelligence | 1.3 | 1.3 | |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 7.2 | 4.6 | 0.57 |
| ischemic stroke | 3.3 | 1.4 | 1.36 |
| Liver Cirrhosis | 7.2 | 5 | 0.44 |
| Long COVID | 4.7 | 6.1 | -0.3 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 1.5 | -0.25 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.6 | 1 |
| ME/CFS with IBS | 0.5 | 1.5 | -2 |
| ME/CFS without IBS | 0.5 | 1.7 | -2.4 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 0.8 | 1 |
| Metabolic Syndrome | 6.8 | 6.9 | -0.01 |
| Mood Disorders | 9.2 | 6 | 0.53 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 5.6 | 3.8 | 0.47 |
| Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 3.1 | -3.1 | |
| Neuropathy (all types) | 0.6 | 2.5 | -3.17 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.7 | 4.2 | 0.36 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 9.5 | 7.7 | 0.23 |
| obsessive-compulsive disorder | 5.1 | 2.4 | 1.13 |
| Osteoarthritis | 2.1 | 1.4 | 0.5 |
| Osteoporosis | 2.2 | 1.7 | 0.29 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.5 | 5.5 | 0.36 |
| Polycystic ovary syndrome | 4.9 | 2.7 | 0.81 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.8 | 1.9 | 0.47 |
| Psoriasis | 3.5 | 1.9 | 0.84 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 3.6 | 0.64 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 5.7 | 3 | 0.9 |
| scoliosis | 0.6 | 0.4 | 0.5 |
| Sjögren syndrome | 2.6 | 2.3 | 0.13 |
| Sleep Apnea | 1.9 | 1.3 | 0.46 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.4 | 4 |
| Stress / posttraumatic stress disorder | 3.5 | 2.3 | 0.52 |
| Systemic Lupus Erythematosus | 3.2 | 2.4 | 0.33 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 3.5 | 3.3 | 0.06 |
| Type 2 Diabetes | 6.6 | 6.7 | -0.02 |
| Ulcerative colitis | 5.5 | 5.2 | 0.06 |
| Unhealthy Ageing | 3 | 1.8 | 0.67 |
| Vitiligo | 2.3 | 1.1 | 1.09 |
